Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

Research backs this up: Young men who consumed more protein while losing weight and on an intense exercise regiment gained ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Dr. Alexandra Sowa, an obesity medicine specialist and author of the new book “The Ozempic Revolution” shares the pros and ...

Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it ...

On the surface, the formula for weight loss seems simple: eat less and move more. But giving that advice to someone with ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...